Fig. 4: FTO mitigates older HIRI by decreasing ferroptosis.

a Serum AST and ALT levels in OLT recipients at POD1 (FTO-Low group, n = 5; FTO-High group, n = 5). All donors were over 50 years old. Recipients were grouped according to the IHC score of FTO in liver tissues. AST and ALT, two-tailed t-test. b Changes in serum AST and AST levels in OLT recipients with different FTO expression levels from POD1 to POD7. AST and ALT, two-tailed t-test. c, d Serum ALT and AST levels of older mice in different groups (n = 3, per group). ALT and AST, one-way ANOVA followed by multiple comparisons. e Representative images and relative quantification/Suzuki score of HE staining (magnification, × 100), TUNEL staining (magnification, × 200), DHE staining (magnification, × 100) and C11 BODIPY staining (magnification, × 200) in older liver tissues with different treatments, one-way ANOVA followed by multiple comparisons. f Representative TEM images. The red arrows indicate the reduction or disappearance of mitochondrial cristae to reflect ferroptosis. g Western blotting showed changes in the expression of key factors related to ferroptosis. f, g Three independent biological mice samples. h Representative images and relative quantification of Calcein-AM/PI double staining (magnification, × 100), DHE staining (magnification, × 200) and C11 BODIPY staining (magnification, × 200) to evaluate the effect of FB23-2 on primary hepatocytes during H/R, one-way ANOVA followed by multiple comparisons. i Effects of erastin on cell death (magnification, × 100), ROS accumulation (magnification, × 200) and lipid peroxidation (magnification, × 200) in primary hepatocytes during H/R, one-way ANOVA followed by multiple comparisons. Statistic data are presented as the mean±SD, error bars represent the means of three independent experiments. P < 0.05 was considered statistically significant. NS no significance, source data are provided as a Source Data file.